Abstract
Twenty-four patients with chronic stable exertional angina pectoris were randomized in a double-blind, placebo-controlled, crossover trial to assess the efficacy and durability of a newly developed sustained-release formulation of nifedipine (nifedipine CC) in a single 40-mg oral dose. Symptom-limited graded treadmill exercise tests were performed just before and at 4, 7, and 24 h after a single administration of the drug or the placebo was given. Exercise tolerance at 4, 7, and 24 h after the drug were compared with the corresponding placebo values. Data could be analysed for 19 patients. Maximal exercise time time to the onset of angina and time to 1 mm ST segment depression were significantly greater at 4, 7, and 24 h after nifedipine CC than at baseline or with the corresponding placebo. The average maximal exercise time was significantly increased by 72, 76 and 37 s at 4, 7, and 24 h. Rate-pressure product at rest and at peak exercise showed significant changes only at 24 h compared with placebo (both P < 0.05). The maximal increase in exercise tolerance was most marked at 7 h after nifedipine CC at which time plasma drug concentration was 99.4 ± 14.0 ng.ml -1 . Thus, in patients with chronic stable exertional angina pectoris nifedipine CC showed a prolonged improvement in exercise tolerance up to 24 h after a single oral administration.
| Original language | English |
|---|---|
| Pages (from-to) | 965-970 |
| Number of pages | 6 |
| Journal | European Heart Journal |
| Volume | 15 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - 01-01-1994 |
| Externally published | Yes |
Fingerprint
All Science Journal Classification (ASJC) codes
- Cardiology and Cardiovascular Medicine
Cite this
}
Duration and extent of antianginal effects of a sustained-release formulation of nifedipine in angina. / Yokota, M.; Saito, F.; Izawa, Hideo; Matsunami, T.; Yoshida, J.; Inagaki, H.; Sotobata, I.
In: European Heart Journal, Vol. 15, No. 7, 01.01.1994, p. 965-970.Research output: Contribution to journal › Article
TY - JOUR
T1 - Duration and extent of antianginal effects of a sustained-release formulation of nifedipine in angina
AU - Yokota, M.
AU - Saito, F.
AU - Izawa, Hideo
AU - Matsunami, T.
AU - Yoshida, J.
AU - Inagaki, H.
AU - Sotobata, I.
PY - 1994/1/1
Y1 - 1994/1/1
N2 - Twenty-four patients with chronic stable exertional angina pectoris were randomized in a double-blind, placebo-controlled, crossover trial to assess the efficacy and durability of a newly developed sustained-release formulation of nifedipine (nifedipine CC) in a single 40-mg oral dose. Symptom-limited graded treadmill exercise tests were performed just before and at 4, 7, and 24 h after a single administration of the drug or the placebo was given. Exercise tolerance at 4, 7, and 24 h after the drug were compared with the corresponding placebo values. Data could be analysed for 19 patients. Maximal exercise time time to the onset of angina and time to 1 mm ST segment depression were significantly greater at 4, 7, and 24 h after nifedipine CC than at baseline or with the corresponding placebo. The average maximal exercise time was significantly increased by 72, 76 and 37 s at 4, 7, and 24 h. Rate-pressure product at rest and at peak exercise showed significant changes only at 24 h compared with placebo (both P < 0.05). The maximal increase in exercise tolerance was most marked at 7 h after nifedipine CC at which time plasma drug concentration was 99.4 ± 14.0 ng.ml -1 . Thus, in patients with chronic stable exertional angina pectoris nifedipine CC showed a prolonged improvement in exercise tolerance up to 24 h after a single oral administration.
AB - Twenty-four patients with chronic stable exertional angina pectoris were randomized in a double-blind, placebo-controlled, crossover trial to assess the efficacy and durability of a newly developed sustained-release formulation of nifedipine (nifedipine CC) in a single 40-mg oral dose. Symptom-limited graded treadmill exercise tests were performed just before and at 4, 7, and 24 h after a single administration of the drug or the placebo was given. Exercise tolerance at 4, 7, and 24 h after the drug were compared with the corresponding placebo values. Data could be analysed for 19 patients. Maximal exercise time time to the onset of angina and time to 1 mm ST segment depression were significantly greater at 4, 7, and 24 h after nifedipine CC than at baseline or with the corresponding placebo. The average maximal exercise time was significantly increased by 72, 76 and 37 s at 4, 7, and 24 h. Rate-pressure product at rest and at peak exercise showed significant changes only at 24 h compared with placebo (both P < 0.05). The maximal increase in exercise tolerance was most marked at 7 h after nifedipine CC at which time plasma drug concentration was 99.4 ± 14.0 ng.ml -1 . Thus, in patients with chronic stable exertional angina pectoris nifedipine CC showed a prolonged improvement in exercise tolerance up to 24 h after a single oral administration.
UR - http://www.scopus.com/inward/record.url?scp=0028240873&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028240873&partnerID=8YFLogxK
U2 - 10.1093/oxfordjournals.eurheartj.a060617
DO - 10.1093/oxfordjournals.eurheartj.a060617
M3 - Article
C2 - 7925519
AN - SCOPUS:0028240873
VL - 15
SP - 965
EP - 970
JO - European Heart Journal
JF - European Heart Journal
SN - 0195-668X
IS - 7
ER -